Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and increased the price target from $72 to $90.
February 27, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on Celldex Therapeutics and raised the price target to $90 from $72.
The upgrade in the price target by a reputable analyst like Yatin Suneja from Guggenheim signals a strong confidence in Celldex Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100